Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the ...

Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies ...

Merck CEO Rob Davis told investors on Thursday that he’s confident in the company’s ability to protect its top-selling ...

The grow­ing drug dis­count pro­gram for low-in­come Amer­i­cans, known as the 340B pro­gram, has “trans­paren­cy and ...

Merck, Bristol Myers Squibb, Sanofi and Roche — were eager to position themselves as fully prepared for whatever may come ...

Only 66% of FDA-approved biosimilars launched, with Humira & Enbrel facing limited competition despite biosimilars priced ...

Lotte Biologics, Ypsomed, PCI Pharma, Samsung Biologics, Catalent & Ferring share manufacturing updates: new ADC services, ...

Thermo Fisher Scientific has warned it could lose out on nearly $1 billion in revenue this year due to the US-China tariff ...

Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported ...

Roche details plans to handle US tariffs, including moving production and building inventory, while Sanofi runs scenarios but ...

But the company is not ruling out future deals, even in its metabolic unit, which recently saw a major partnership with ...

Tempus AI expands deals with AstraZeneca and Pathos for $200M, Avidicure raises $50M seed round, Bioxodes reports Phase 2a ...